267 related articles for article (PubMed ID: 25664601)
41. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.
Bodei L; Kidd M; Modlin IM; Severi S; Drozdov I; Nicolini S; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):839-851. PubMed ID: 26596723
[TBL] [Abstract][Full Text] [Related]
42. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
[TBL] [Abstract][Full Text] [Related]
43. A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms.
Kruljac I; Vurnek I; Maasberg S; Kust D; Blaslov K; Ladika Davidović B; Štefanović M; Demirović A; Bišćanin A; Filipović-Čugura J; Marić Brozić J; Pape UF; Vrkljan M
Endocrine; 2018 Jun; 60(3):395-406. PubMed ID: 29633144
[TBL] [Abstract][Full Text] [Related]
44. Chromogranin Serves as Novel Biomarker of Endocrine and Gastric Autoimmunity.
Ebert A; König J; Frommer L; Schuppan D; Kahaly GJ
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32436949
[TBL] [Abstract][Full Text] [Related]
45. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
[TBL] [Abstract][Full Text] [Related]
46. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors.
Pulvirenti A; Rao D; Mcintyre CA; Gonen M; Tang LH; Klimstra DS; Fleisher M; Ramanathan LV; Reidy-Lagunes D; Allen PJ
HPB (Oxford); 2019 May; 21(5):612-618. PubMed ID: 30366884
[TBL] [Abstract][Full Text] [Related]
47. Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.
Corsello A; Di Filippo L; Massironi S; Sileo F; Dolcetta Capuzzo A; Gemma M; Carlucci C; Cusini C; Colombo B; Dallatomasina A; Franchi GM; Corti A; Manzoni MF
PLoS One; 2018; 13(5):e0196858. PubMed ID: 29723285
[TBL] [Abstract][Full Text] [Related]
48. Effect of short- and long-term physical activities on circulating granin protein levels.
Røsjø H; Opstad PK; Hoff JE; Godang K; Christensen G; Stridsberg M; Omland T
Regul Pept; 2013 Aug; 185():14-9. PubMed ID: 23816467
[TBL] [Abstract][Full Text] [Related]
49. Octreotide suppression test in diagnosing and predicting the outcome of therapy in patients with neuroendocrine tumors. Preliminary report.
Kos-Kudła B; Zemczak A; Foltyn W; Marek B; Strzelczyk J; Telega A; Zajecki W; Legaszewski T; Jurecka-Lubieniecka B
Endokrynol Pol; 2007; 58(2):123-9. PubMed ID: 17578828
[TBL] [Abstract][Full Text] [Related]
50. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
[TBL] [Abstract][Full Text] [Related]
51. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
[TBL] [Abstract][Full Text] [Related]
52. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
[TBL] [Abstract][Full Text] [Related]
53. Chromogranin A: is it a useful marker of neuroendocrine tumors?
Campana D; Nori F; Piscitelli L; Morselli-Labate AM; Pezzilli R; Corinaldesi R; Tomassetti P
J Clin Oncol; 2007 May; 25(15):1967-73. PubMed ID: 17513802
[TBL] [Abstract][Full Text] [Related]
54. Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.
Fisher AV; Lopez-Aguiar AG; Rendell VR; Pokrzywa C; Rocha FG; Kanji ZS; Poultsides GA; Makris EA; Dillhoff ME; Beal EW; Fields RC; Panni RZ; Idrees K; Smith PM; Cho CS; Beems MV; Maithel SK; Winslow ER; Abbott DE; Weber SM
J Gastrointest Surg; 2019 Apr; 23(4):651-658. PubMed ID: 30659439
[TBL] [Abstract][Full Text] [Related]
55. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive.
Pavel M; Jann H; Prasad V; Drozdov I; Modlin IM; Kidd M
Neuroendocrinology; 2017; 104(2):170-182. PubMed ID: 27078712
[TBL] [Abstract][Full Text] [Related]
56. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
[TBL] [Abstract][Full Text] [Related]
57. Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan.
Giovanella L; Squin N; Ghelfo A; Ceriani L
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):344-7. PubMed ID: 17043632
[TBL] [Abstract][Full Text] [Related]
58. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1.
Peracchi M; Conte D; Gebbia C; Penati C; Pizzinelli S; Arosio M; Corbetta S; Spada A
Eur J Endocrinol; 2003 Jan; 148(1):39-43. PubMed ID: 12534356
[TBL] [Abstract][Full Text] [Related]
59. Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma.
Lee SH; Jo JH; Kim YJ; Lee HS; Chung MJ; Park JY; Bang S; Park SW; Song SY
Pancreas; 2019; 48(5):662-669. PubMed ID: 31091213
[TBL] [Abstract][Full Text] [Related]
60. Use of Chromogranin A for Monitoring Patients With Pancreatic Neuroendocrine Neoplasms.
Yu F; Fu J; Zhang C; Wu W; Ai S; Yao X; Meng Q; Huang Y; Lu G; Wang F; Qu W
Pancreas; 2021 Jul; 50(6):882-889. PubMed ID: 34347728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
